EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sickle cell disease in Germany – trends in epidemiology, healthcare utilization and disease burden from 2015 to 2024: a claims data analysis

Nils Schulze, Moritz Lehne, Anja Cengia, Klara Sonnie Hinrichsmeyer, Agnes Kisser, Ferras Alashkar, Caoimhe Cawley

Annals of Hematology · 23.10.2026 · 105 (11)

DOI: 10.1007/s00277-026-07308-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 23.10.2026. Verfasst von Nils Schulze und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health Services and Health Systems Research, Immanuel Clinic Rüdersdorf, Medical University Brandenburg Theodor Fontane, Seebad 82/83, 1…. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Patient Acceptance of Health Care, Cost of Illness. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sickle cell disease (SCD) is a rare inherited hemoglobinopathy associated with substantial morbidity and high healthcare needs. In Germany, population-based evidence on SCD epidemiology and real-world care patterns remains limited, despite increasing relevance in the context of migration and the introduction of nationwide newborn screening in 2021.

Methods

We conducted a retrospective, non-interventional study using anonymized German statutory health insurance claims data from the InGef database (2015–2024). Patients with SCD were identified using ICD-10-GM codes D57.0, D57.1, D57.2, and D57.8 based on inpatient and confirmed outpatient diagnoses. Administrative prevalence was estimated using a carry-forward cohort approach, whereby SCD patients diagnosed in the current year and alive/observable in subsequent years were counted as prevalent. Administrative incidence was assessed in children aged < 6 years using the first recorded SCD diagnosis in claims data as the date of incidence. Analyses of patient characteristics, clinical outcomes, treatments and healthcare resource use (HCRU) were conducted cross-sectionally by calendar year, stratified by age group and sex.

Results

Across 2015–2024, 1,019 individuals with SCD were identified. As might be expected using a carry forward cohort approach, annual prevalent counts increased from 225 (2015) to 864 (2024), and nationally extrapolated prevalence increased from 2.75 per 100,000 in 2015 to 10.50 per 100,000 in 2024. Median time to recorded diagnosis in children < 6 years decreased from 31 months (2015) to 11 months from 2021 onwards (2021–2024). In 2024, infections were the most frequently documented clinical outcome (34.5% [298/864]), followed by vaso‑occlusive crises (19.2% [166/864]) and mental health comorbidities (depression 19.1% [165/864]; anxiety 9.1% [79/864]). The proportions of patients with inpatient or outpatient visits, and with medication prescriptions (e.g. for antibiotics, antirheumatics, hydroxyurea), decreased over time.

Conclusion

This claims-based analysis indicates increasing documented SCD prevalence in Germany. However, the extent to which prevalence increased due to a true increase in the general population, due to our carry-forward cohort approach, or due to other factors such as changes in coding practices or healthcare seeking behaviors, cannot be disentangled.We observed earlier recorded diagnosis timing in young children over time, alongside substantial age-dependent burden reflected in complications, mental health comorbidity, and healthcare utilization. Possible explanations for lower proportions of patients with inpatient/outpatient visits and medication prescriptions over time may include changes in disease awareness, patient management and/or healthcare seeking behaviours over time, and/or broader capture of patients with milder disease. Overall, our findings can inform healthcare planning and structured life-course–oriented SCD care pathways in Germany.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellPatient Acceptance of Health CareCost of IllnessHumansGermanyFemaleMaleRetrospective StudiesChild, PreschoolChildInfantAdolescentAdultInfant, NewbornYoung AdultPrevalenceCross-Sectional StudiesMiddle AgedIncidenceInsurance Claim ReviewDatabases, Factual

Stichwörter der Autor:innen

Claims dataEpidemiologyHealthcare resource utilization (HCRU)IncidencePrevalenceSickle cell disease

Autor:innen und Institutionen

  • Institute of Health Services and Health Systems Research, Immanuel Clinic Rüdersdorf, Medical University Brandenburg Theodor Fontane, Seebad 82/83, 15562, Rüdersdorf bei Berlin, Germany. nils.schulze@mhb-fontane.de.
  • Pfizer Pharma GmbH, Friedrichstraße 110, 10117, Berlin, Germany. nils.schulze@mhb-fontane.de.
  • Cytel Inc, Potsdamer Straße 58, 10785, Berlin, Germany.
  • InGef - Institute for Applied Health Research Berlin GmbH, Otto-Ostrowski- Straße 5, 10249, Berlin, Germany.
  • Pfizer Pharma GmbH, Friedrichstraße 110, 10117, Berlin, Germany.
  • Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany.

Förderung

  • Pfizer Pharma

Zitieren

APA

Schulze, N., Lehne, M., Cengia, A., Hinrichsmeyer, K. S., Kisser, A., Alashkar, F., & Cawley, C. (2026). Sickle cell disease in Germany – trends in epidemiology, healthcare utilization and disease burden from 2015 to 2024: a claims data analysis. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07308-2

Vancouver

Schulze N, Lehne M, Cengia A, Hinrichsmeyer KS, Kisser A, Alashkar F, et al. Sickle cell disease in Germany – trends in epidemiology, healthcare utilization and disease burden from 2015 to 2024: a claims data analysis. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07308-2

BibTeX
@article{Schulze2026,
  author = {Schulze, Nils and Lehne, Moritz and Cengia, Anja and Hinrichsmeyer, Klara Sonnie and Kisser, Agnes and Alashkar, Ferras and Cawley, Caoimhe},
  title = {Sickle cell disease in Germany – trends in epidemiology, healthcare utilization and disease burden from 2015 to 2024: a claims data analysis},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {11},
  doi = {10.1007/s00277-026-07308-2}
}
Kostenlos starten →